The Utility of Metformin Therapy in Reproductive-Aged Women with Polycystic Ovary Syndrome (PCOS)

Author(s): Nisha Nathan, Shannon D. Sullivan

Journal Name: Current Pharmaceutical Biotechnology

Volume 15 , Issue 1 , 2014

Become EABM
Become Reviewer
Call for Editor


Metformin, an insulin-sensitizing drug commonly used to treat Type 2 Diabetes Mellitus (T2DM), has been increasingly used off-label for the treatment of polycystic ovary syndrome (PCOS), which affects at least 5-10% of reproductive- age women. With very little risk associated with its use, metformin provides many important benefits to women with PCOS, including regulating menstrual cycles, improving clinical signs of hyperandrogenism, ameliorating metabolic syndrome, inducing ovulation, improving pregnancy rates and pregnancy outcomes, preventing gestational diabetes, and preventing progression to T2DM. Here, we review the indications for metformin in women with PCOS, with a focus on the use of metformin during pre-conception and pregnancy.

Keywords: Gestational diabetes mellitus, hirsutism, infertility, insulin resistance, metabolic syndrome, metformin, polycystic ovary syndrome, pregnancy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [70 - 83]
Pages: 14
DOI: 10.2174/1389201015666140330195142
Price: $65

Article Metrics

PDF: 96